Business
Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and
About this update from Immunome, Inc.
[{"type":"text","content":" BOTHELL, Wash.--(BUSINESS WIRE)--\nImmunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that data from RINGSIDE, its global, Phase 3, randomized, placebo-controlled trial of varegacestat in patients with progressing desmoid tumors, has been selected for presentation in an oral abstract session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29–June 2, 2026, in Chicago.\n\n\n“The selection of the Phase 3 RINGSIDE trial for oral presentation at ASCO reflects the importance of advancing new treatment options for patients with desmoid tumors,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer. “We look forward to sharing detailed results that build on the positive topline data reported in December 2025.”\n\n\nOral Presentation Details\n\n\n\n\nAbstract Title\n\n\n\n\n\n\nRINGSIDE: A phase 3 randomized, placebo-controlled trial of varegacestat for treatment of progressing desmoid tumors\n\n\n\n\n\n\n\n\nSession Type/Title\n\n\n\n\n\n\nOral Abstract Session – Sarcoma\n\n\n\n\n\n\n\n\nDate and Time\n\n\n\n\n\n\nMay 30, 2026, 3:00 PM–6:00 PM CDT\n\n\n\n\n\n\n\n\nPresenter\n\n\n\n\n\n\nMrinal M. Gounder, M.D., Memorial Sloan Kettering Cancer Center\n\n\n\n\n\n\n\n\nAbstract Number\n\n\n\n\n\n\n11506\n\n\n\n\n\n\n\nAbout the RINGSIDE Trial\n\n\nThe global, randomized, double-blind, placebo-controlled Phase 3 RINGSIDE trial (NCT04871282) evaluated the efficacy and safety of varegacestat in patients with progressing desmoid tumors. A total of 156 patients were randomized to receive varegacestat 1.2 mg daily or placebo until disease progression or death, representing the largest randomized study in this population. The primary endpoint of the trial was progression-free survival as assessed by blinded independent central review. Statistically controlled secondary endpoints were confirmed ORR using RECIST v1.1 and change in tumor volume at week 24, both determined by blinded independent central review, as well as change in pain intensity at week 12 as determined using a patient reported outcome instrument. Additional secondary endpoints included duration of response, best reduction in tumor volume, patient-reported outcomes, and safety and tolerability. RINGSIDE includes ...